Canada Journal – News of the World Articles and videos to bring you the biggest Canadian news stories from across the country every day
The U.S. Food and Drug Administration has approved a new Cubist Pharmaceuticals (NASDAQ: CBST) antibiotic targeting a variety of skin infections, most notably those caused by the so-called MRSA bacteria, which has been named a serious public health threat by the U.S Centers for Disease Control and Prevention, according to a Cubist announcement.
The drug works against a variety of common bacteria, including Staphylococcus aureus, Streptococcus species and Enterococcus faecalis.
The Centers for Disease Control and Prevention estimated last year that the staph infection methicillin-resistant Staphylococcus aureus, or MRSA, kills about 11,000 people annually.
Many different types of common bacteria have grown resistant to antibiotics that we once effective in treating them in the past. Researcher have concluded that overuse by physicians has been a factor. The FDA gave Sivextro an expedited review under a 2012 law designed to encourage drugmakers to invest in researching and development of new antibiotics.
Shares of Cubist Pharmaceuticals (CBST) closed up 5.38%, + $3.69 yesterday to $72.24 on moderately higher volume. and rose another $1.26, or 1.7 percent, to $73.50 in afterhours trading.
Cubist Pharmaceuticals (CBST), a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States.
Agencies/Canadajournal
